Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.

In this study, we apply a latent time joint mixed-effects model to study biomarker progression and disease dynamics in the Parkinson's Progression Markers Initiative (PPMI) and examine which markers might be most informative in the earliest phases of disease. The results reveal that, even though diagnostic category was not included in the model, it seems to accurately reflect the temporal ordering of the disease state consistent with diagnosis categorization at baseline. In addition, results indicated that the specific binding ratio on striatum and the total Unified Parkinson's Disease Rating Scale (UPDRS) show high discriminability between disease stages. An extended latent time joint mixed-effects model with heterogeneous latent time variance also showed improvement in model fit in a simulation study and when applied to real data. PMID: 30089306 [PubMed - as supplied by publisher]
Source: Neuro-Degenerative Diseases - Category: Neurology Authors: Tags: Neurodegener Dis Source Type: research

Related Links:

Conclusion The patients in the DAT-positive group might have prodromal symptoms that were worsened by neuroleptic drugs. The results of detailed history-taking and neurological findings seem to indicate cases of compromised dopaminergic transmission before the administration of neuroleptic drugs. PMID: 32062624 [PubMed - in process]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Conclusion: More data concerning the safety of antiparkinsonian drugs in PD treatment, as well as the effect of pregnancy on parkinsonian symptoms are needed. According to the current state of the art, L-DOPA therapy should be considered preferable to other drugs during pregnancy.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Condition:   Parkinson Disease Intervention:   Device: Auditive cueing Sponsors:   Ceriter Nederland BV;   Ziekenhuis Oost Limburg (ZOL) Hospital Genk, Belgium Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Intervention:   Drug: Lithium Sponsor:   University at Buffalo Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Parkinson Disease;   Cognitive Impairment, Mild;   Speech Interventions:   Diagnostic Test: Cognitive Battery;   Behavioral: Voice, Speech and Language Analysis;   Behavioral: Questionnaires and Clinical Assessments;   Genetic: DNA Analysis Sponsors:   University of Massachusetts, Worcester;   Sonde Health, Inc.;   Massachusetts Institute of Technology/Lincoln Labs;   Boston University;   VA Puget Sound Health Care System Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Intervention:   Drug: Lithium Sponsor:   University at Buffalo Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Parkinson Disease;   Cognitive Impairment, Mild;   Speech Interventions:   Diagnostic Test: Cognitive Battery;   Behavioral: Voice, Speech and Language Analysis;   Behavioral: Questionnaires and Clinical Assessments;   Genetic: DNA Analysis Sponsors:   University of Massachusetts, Worcester;   Sonde Health, Inc.;   Massachusetts Institute of Technology/Lincoln Labs;   Boston University;   VA Puget Sound Health Care System Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Intervention:   Device: Auditive cueing Sponsors:   Ceriter Nederland BV;   Ziekenhuis Oost Limburg (ZOL) Hospital Genk, Belgium Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 17 February 2020Source: Neuroscience &Biobehavioral ReviewsAuthor(s): Zhike Zhou, Yifan Liang, Xiaoqian Zhang, Junjie Xu, Jueying Lin, Rongwei Zhang, Kexin Kang, Huiling Qu, Chuansheng Zhao, Mei ZhaoAbstractBackgroundThe aim of this meta-analysis is to evaluate the association of fibrinogen with risk of dementia and its subtypes.MethodsEmbase, Pubmed and Web of Science were retrieved systematically up to February 2019. Standard mean difference (SMD) with 95% confidence intervals was estimated using random-effects models.ResultsSixteen studies involving 3,649 participants were summariz...
Source: Neuroscience and Biobehavioral Reviews - Category: Neuroscience Source Type: research
For a variety of sporadic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis, it is well-established that ethnicity do affect the disease phenotypes. However, how the ethnicity could contribute to the clinical symptoms and disease progressions in monogenetic disorders, such as spinocerebellar ataxia type 3 (SCA3), remains less studied.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Source Type: research
More News: Brain | Neurology | Parkinson's Disease | Statistics | Study